Bulletin
Investor Alert

London Markets Open in:

press release

April 15, 2022, 8:31 a.m. EDT

Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern Time

NORTH BILLERICA, Apr 15, 2022 (GLOBE NEWSWIRE via COMTEX) -- NORTH BILLERICA, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") /zigman2/quotes/204144070/composite LNTH -3.47% today announced that it will host a conference call and webcast at 8:00 a.m. ET on Friday, April 29, 2022, to discuss its financial and operating results for the first quarter of 2022.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 8691334. A live webcast will also be available in the Investors section of the Company's website at www.lantheus.com .

A replay of the webcast will be available in the Investors section of the Company's website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow [(R)] serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY [(R)] Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY [(R)] , a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI [(TM)] , an artificial intelligence platform that assists in the evaluation of PSMA PET images; TechneLite [(R)] (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA [(R)] for the treatment of certain rare neuroendocrine tumors; and RELISTOR [(R)] for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts, with additional offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com .

Contacts:

Mark Kinarney
Senior Director, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com

COMTEX_405742734/2471/2022-04-15T08:30:31

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/204144070/composite
US : U.S.: Nasdaq
$ 68.36
-2.46 -3.47%
Volume: 1.06M
Sept. 23, 2022 4:00p
P/E Ratio
159.27
Dividend Yield
N/A
Market Cap
$4.70 billion
Rev. per Employee
$1.09M
loading...

Partner Center

Link to MarketWatch's Slice.